img

Global Acute Vulvovaginal Candidiasis Treatment Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Acute Vulvovaginal Candidiasis Treatment Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application

Acute vulvovaginal candidiasis is a fungal/yeast infection, which is caused by some species of Candida, especially Candida albicans. Increasing cases of vulvovaginal candidiasis can be attributed to ageing, overuse of antibiotics, diabetes, etc. Doctors are involved in prescribing medicines on the basis of their efficiency in controlling acute vulvovaginal candidiasis among the patients.
Acute Vulvovaginal Candidiasis Treatment report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Acute Vulvovaginal Candidiasis Treatment market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Acute Vulvovaginal Candidiasis Treatment industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Acute Vulvovaginal Candidiasis Treatment key companies include Mycovia Pharmaceuticals, Inc, Scynexis, Inc, Basilea Pharmaceutica Ltd, Astellas Pharma Inc, Grupo Ferrer Internacional, S.A, Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc, Cidara Therapeutics, Inc and Amplyx Pharmaceuticals Inc, etc. Mycovia Pharmaceuticals, Inc, Scynexis, Inc, Basilea Pharmaceutica Ltd are top 3 players and held % share in total in 2022.
Acute Vulvovaginal Candidiasis Treatment can be divided into Clotrimazole, Nystatin, Fluconazole and Ketoconazole, etc. Clotrimazole is the mainstream product in the market, accounting for % share globally in 2022.
Acute Vulvovaginal Candidiasis Treatment is widely used in various fields, such as Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, etc. Hospital Pharmacies provides greatest supports to the Acute Vulvovaginal Candidiasis Treatment industry development. In 2022, global % share of Acute Vulvovaginal Candidiasis Treatment went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Acute Vulvovaginal Candidiasis Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Mycovia Pharmaceuticals, Inc
Scynexis, Inc
Basilea Pharmaceutica Ltd
Astellas Pharma Inc
Grupo Ferrer Internacional, S.A
Pacgen Life Science Corporation
NovaDigm Therapeutics, Inc
Cidara Therapeutics, Inc
Amplyx Pharmaceuticals Inc
Pfizer, Inc.
Segment by Type
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others

Segment by Application


Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Acute Vulvovaginal Candidiasis Treatment market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Acute Vulvovaginal Candidiasis Treatment introduction, etc. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Acute Vulvovaginal Candidiasis Treatment market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Market Overview of Acute Vulvovaginal Candidiasis Treatment
1.1 Acute Vulvovaginal Candidiasis Treatment Market Overview
1.1.1 Acute Vulvovaginal Candidiasis Treatment Product Scope
1.1.2 Acute Vulvovaginal Candidiasis Treatment Market Status and Outlook
1.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size Overview by Region 2024 VS 2022 VS 2034
1.3 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2024-2034)
1.4 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Region (2024-2024)
1.5 Global Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Region (2024-2034)
1.6 Key Regions, Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034)
1.6.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034)
1.6.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034)
1.6.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034)
1.6.4 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034)
1.6.5 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034)
2 Acute Vulvovaginal Candidiasis Treatment Market by Type
2.1 Introduction
2.1.1 Clotrimazole
2.1.2 Nystatin
2.1.3 Fluconazole
2.1.4 Ketoconazole
2.1.5 Terbinafine
2.1.6 Terconazole
2.1.7 Others
2.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type: 2024 VS 2022 VS 2034
2.2.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Type (2024-2024)
2.2.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Type (2024-2034)
2.3 Key Regions Market Size by Type
2.3.1 North America Acute Vulvovaginal Candidiasis Treatment Revenue Breakdown by Type (2024-2034)
2.3.2 Europe Acute Vulvovaginal Candidiasis Treatment Revenue Breakdown by Type (2024-2034)
2.3.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Revenue Breakdown by Type (2024-2034)
2.3.4 Latin America Acute Vulvovaginal Candidiasis Treatment Revenue Breakdown by Type (2024-2034)
2.3.5 Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Revenue Breakdown by Type (2024-2034)
3 Acute Vulvovaginal Candidiasis Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application: 2024 VS 2022 VS 2034
3.2.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Application (2024-2024)
3.2.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Application (2024-2034)
3.3 Key Regions Market Size by Application
3.3.1 North America Acute Vulvovaginal Candidiasis Treatment Revenue Breakdown by Application (2024-2034)
3.3.2 Europe Acute Vulvovaginal Candidiasis Treatment Revenue Breakdown by Application (2024-2034)
3.3.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Revenue Breakdown by Application (2024-2034)
3.3.4 Latin America Acute Vulvovaginal Candidiasis Treatment Revenue Breakdown by Application (2024-2034)
3.3.5 Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Revenue Breakdown by Application (2024-2034)
4 Acute Vulvovaginal Candidiasis Treatment Competition Analysis by Players
4.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Players (2024-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Acute Vulvovaginal Candidiasis Treatment as of 2022)
4.3 Date of Key Players Enter into Acute Vulvovaginal Candidiasis Treatment Market
4.4 Global Top Players Acute Vulvovaginal Candidiasis Treatment Headquarters and Area Served
4.5 Key Players Acute Vulvovaginal Candidiasis Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Acute Vulvovaginal Candidiasis Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Mycovia Pharmaceuticals, Inc
5.1.1 Mycovia Pharmaceuticals, Inc Profile
5.1.2 Mycovia Pharmaceuticals, Inc Main Business
5.1.3 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
5.1.4 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) & (2024-2024)
5.1.5 Mycovia Pharmaceuticals, Inc Recent Developments
5.2 Scynexis, Inc
5.2.1 Scynexis, Inc Profile
5.2.2 Scynexis, Inc Main Business
5.2.3 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
5.2.4 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) & (2024-2024)
5.2.5 Scynexis, Inc Recent Developments
5.3 Basilea Pharmaceutica Ltd
5.3.1 Basilea Pharmaceutica Ltd Profile
5.3.2 Basilea Pharmaceutica Ltd Main Business
5.3.3 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
5.3.4 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) & (2024-2024)
5.3.5 Astellas Pharma Inc Recent Developments
5.4 Astellas Pharma Inc
5.4.1 Astellas Pharma Inc Profile
5.4.2 Astellas Pharma Inc Main Business
5.4.3 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
5.4.4 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) & (2024-2024)
5.4.5 Astellas Pharma Inc Recent Developments
5.5 Grupo Ferrer Internacional, S.A
5.5.1 Grupo Ferrer Internacional, S.A Profile
5.5.2 Grupo Ferrer Internacional, S.A Main Business
5.5.3 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
5.5.4 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) & (2024-2024)
5.5.5 Grupo Ferrer Internacional, S.A Recent Developments
5.6 Pacgen Life Science Corporation
5.6.1 Pacgen Life Science Corporation Profile
5.6.2 Pacgen Life Science Corporation Main Business
5.6.3 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
5.6.4 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) & (2024-2024)
5.6.5 Pacgen Life Science Corporation Recent Developments
5.7 NovaDigm Therapeutics, Inc
5.7.1 NovaDigm Therapeutics, Inc Profile
5.7.2 NovaDigm Therapeutics, Inc Main Business
5.7.3 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
5.7.4 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) & (2024-2024)
5.7.5 NovaDigm Therapeutics, Inc Recent Developments
5.8 Cidara Therapeutics, Inc
5.8.1 Cidara Therapeutics, Inc Profile
5.8.2 Cidara Therapeutics, Inc Main Business
5.8.3 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
5.8.4 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) & (2024-2024)
5.8.5 Cidara Therapeutics, Inc Recent Developments
5.9 Amplyx Pharmaceuticals Inc
5.9.1 Amplyx Pharmaceuticals Inc Profile
5.9.2 Amplyx Pharmaceuticals Inc Main Business
5.9.3 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
5.9.4 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) & (2024-2024)
5.9.5 Amplyx Pharmaceuticals Inc Recent Developments
5.10 Pfizer, Inc.
5.10.1 Pfizer, Inc. Profile
5.10.2 Pfizer, Inc. Main Business
5.10.3 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
5.10.4 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) & (2024-2024)
5.10.5 Pfizer, Inc. Recent Developments
6 North America
6.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2034)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2034)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2024-2034)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2034)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2034)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Acute Vulvovaginal Candidiasis Treatment Market Dynamics
11.1 Acute Vulvovaginal Candidiasis Treatment Industry Trends
11.2 Acute Vulvovaginal Candidiasis Treatment Market Drivers
11.3 Acute Vulvovaginal Candidiasis Treatment Market Challenges
11.4 Acute Vulvovaginal Candidiasis Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million) Comparison by Region 2024 VS 2022 VS 2034
Table 2. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2024-2024) & (US$ Million)
Table 3. Global Acute Vulvovaginal Candidiasis Treatment Market Size Share by Region (2024-2024)
Table 4. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 5. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size Share by Region (2024-2034)
Table 6. Global Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million) by Type: 2024 VS 2022 VS 2034
Table 7. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2024-2024) & (US$ Million)
Table 8. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2024-2024)
Table 9. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 10. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2024-2034)
Table 11. North America Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2024-2024) & (US$ Million)
Table 12. North America Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 13. Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2024-2024) & (US$ Million)
Table 14. Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 15. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2024-2024) & (US$ Million)
Table 16. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 17. Latin America Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2024-2024) & (US$ Million)
Table 18. Latin America Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 19. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2024-2024) & (US$ Million)
Table 20. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 21. Global Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million) by Application: 2024 VS 2022 VS 2034
Table 22. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2024-2024) & (US$ Million)
Table 23. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2024-2024)
Table 24. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2024-2034)
Table 26. North America Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2024-2024) & (US$ Million)
Table 27. North America Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 28. Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2024-2024) & (US$ Million)
Table 29. Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 30. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2024-2024) & (US$ Million)
Table 31. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 32. Latin America Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2024-2024) & (US$ Million)
Table 33. Latin America Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 34. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2024-2024) & (US$ Million)
Table 35. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 36. Global Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) by Players (2024-2024)
Table 37. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Players (2024-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Acute Vulvovaginal Candidiasis Treatment as of 2022)
Table 39. Date of Key Players Enter into Acute Vulvovaginal Candidiasis Treatment Market
Table 40. Global Acute Vulvovaginal Candidiasis Treatment Key Players Headquarters and Area Served
Table 41. Acute Vulvovaginal Candidiasis Treatment Product Solution and Service
Table 42. Global Acute Vulvovaginal Candidiasis Treatment Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Mycovia Pharmaceuticals, Inc Basic Information List
Table 45. Mycovia Pharmaceuticals, Inc Description and Business Overview
Table 46. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
Table 47. Revenue (US$ Million) in Acute Vulvovaginal Candidiasis Treatment Business of Mycovia Pharmaceuticals, Inc (2024-2024)
Table 48. Mycovia Pharmaceuticals, Inc Recent Developments
Table 49. Scynexis, Inc Basic Information List
Table 50. Scynexis, Inc Description and Business Overview
Table 51. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
Table 52. Revenue (US$ Million) in Acute Vulvovaginal Candidiasis Treatment Business of Scynexis, Inc (2024-2024)
Table 53. Scynexis, Inc Recent Developments
Table 54. Basilea Pharmaceutica Ltd Basic Information List
Table 55. Basilea Pharmaceutica Ltd Description and Business Overview
Table 56. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
Table 57. Revenue (US$ Million) in Acute Vulvovaginal Candidiasis Treatment Business of Basilea Pharmaceutica Ltd (2024-2024)
Table 58. Basilea Pharmaceutica Ltd Recent Developments
Table 59. Astellas Pharma Inc Basic Information List
Table 60. Astellas Pharma Inc Description and Business Overview
Table 61. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
Table 62. Revenue (US$ Million) in Acute Vulvovaginal Candidiasis Treatment Business of Astellas Pharma Inc (2024-2024)
Table 63. Astellas Pharma Inc Recent Developments
Table 64. Grupo Ferrer Internacional, S.A Basic Information List
Table 65. Grupo Ferrer Internacional, S.A Description and Business Overview
Table 66. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
Table 67. Revenue (US$ Million) in Acute Vulvovaginal Candidiasis Treatment Business of Grupo Ferrer Internacional, S.A (2024-2024)
Table 68. Grupo Ferrer Internacional, S.A Recent Developments
Table 69. Pacgen Life Science Corporation Basic Information List
Table 70. Pacgen Life Science Corporation Description and Business Overview
Table 71. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
Table 72. Revenue (US$ Million) in Acute Vulvovaginal Candidiasis Treatment Business of Pacgen Life Science Corporation (2024-2024)
Table 73. Pacgen Life Science Corporation Recent Developments
Table 74. NovaDigm Therapeutics, Inc Basic Information List
Table 75. NovaDigm Therapeutics, Inc Description and Business Overview
Table 76. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
Table 77. Revenue (US$ Million) in Acute Vulvovaginal Candidiasis Treatment Business of NovaDigm Therapeutics, Inc (2024-2024)
Table 78. NovaDigm Therapeutics, Inc Recent Developments
Table 79. Cidara Therapeutics, Inc Basic Information List
Table 80. Cidara Therapeutics, Inc Description and Business Overview
Table 81. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
Table 82. Revenue (US$ Million) in Acute Vulvovaginal Candidiasis Treatment Business of Cidara Therapeutics, Inc (2024-2024)
Table 83. Cidara Therapeutics, Inc Recent Developments
Table 84. Amplyx Pharmaceuticals Inc Basic Information List
Table 85. Amplyx Pharmaceuticals Inc Description and Business Overview
Table 86. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
Table 87. Revenue (US$ Million) in Acute Vulvovaginal Candidiasis Treatment Business of Amplyx Pharmaceuticals Inc (2024-2024)
Table 88. Amplyx Pharmaceuticals Inc Recent Developments
Table 89. Pfizer, Inc. Basic Information List
Table 90. Pfizer, Inc. Description and Business Overview
Table 91. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Products, Services and Solutions
Table 92. Revenue (US$ Million) in Acute Vulvovaginal Candidiasis Treatment Business of Pfizer, Inc. (2024-2024)
Table 93. Pfizer, Inc. Recent Developments
Table 94. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 95. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 96. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 97. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 98. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 99. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2024-2024) & (US$ Million)
Table 100. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2024-2034) & (US$ Million)
Table 101. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2024-2024)
Table 102. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2024-2034)
Table 103. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 104. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 105. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 106. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 107. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 108. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 109. Acute Vulvovaginal Candidiasis Treatment Market Trends
Table 110. Acute Vulvovaginal Candidiasis Treatment Market Drivers
Table 111. Acute Vulvovaginal Candidiasis Treatment Market Challenges
Table 112. Acute Vulvovaginal Candidiasis Treatment Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Acute Vulvovaginal Candidiasis Treatment Market Size Year-over-Year 2024-2034 & (US$ Million)
Figure 2. Global Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million), 2024 VS 2022 VS 2034
Figure 3. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Regions: 2022 VS 2034
Figure 4. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size Share by Region (2024-2034)
Figure 5. North America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 6. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 7. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 8. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 9. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 10. Product Picture of Clotrimazole
Figure 11. Global Clotrimazole Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 12. Product Picture of Nystatin
Figure 13. Global Nystatin Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 14. Product Picture of Fluconazole
Figure 15. Global Fluconazole Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 16. Product Picture of Ketoconazole
Figure 17. Global Ketoconazole Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 18. Product Picture of Terbinafine
Figure 19. Global Terbinafine Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 20. Product Picture of Terconazole
Figure 21. Global Terconazole Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 22. Product Picture of Others
Figure 23. Global Others Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 24. Global Acute Vulvovaginal Candidiasis Treatment Market Size Share by Type: 2022 & 2034
Figure 25. North America Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2024-2034)
Figure 26. Europe Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2024-2034)
Figure 27. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2024-2034)
Figure 28. Latin America Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2024-2034)
Figure 29. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2024-2034)
Figure 30. Hospital Pharmacies Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 31. Retail Pharmacies Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 32. Online Pharmacies Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 33. Global Acute Vulvovaginal Candidiasis Treatment Market Size Share by Application: 2022 & 2034
Figure 34. North America Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2024-2034)
Figure 35. Europe Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2024-2034)
Figure 36. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2024-2034)
Figure 37. Latin America Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2024-2034)
Figure 38. Middle East and Africa Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2024-2034)
Figure 39. Acute Vulvovaginal Candidiasis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 40. Global Top 5 and Top 10 Players Acute Vulvovaginal Candidiasis Treatment Market Share in 2022
Figure 41. North America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2024-2034)
Figure 42. United States Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 43. Canada Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 44. Germany Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 45. France Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 46. U.K. Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 47. Italy Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 48. Russia Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 49. Nordic Countries Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 50. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2024-2034)
Figure 51. China Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 52. Japan Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 53. South Korea Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 54. Southeast Asia Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 55. India Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 56. Australia Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 57. Latin America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2024-2034)
Figure 58. Mexico Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 59. Brazil Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 60. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2024-2034)
Figure 61. Turkey Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 62. Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 63. UAE Acute Vulvovaginal Candidiasis Treatment Market Size (2024-2034) & (US$ Million)
Figure 64. Bottom-up and Top-down Approaches for This Report

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries